

**NEWS RELEASE
FOR IMMEDIATE RELEASE**

Hologic Signs Licensing Agreement With The Johns Hopkins University on Hip Structure Analysis

BEDFORD, Mass., (February 6, 2006) -- Hologic, Inc. (NASDAQ: HOLX), today announced they have signed a licensing agreement with The Johns Hopkins University and the Applied Physics Laboratory to integrate the work of Professor Thomas J. Beck, ScD and his colleagues on Hip Structure Analysis (HSA™) into Hologic densitometers.

Dr. Beck, Associate Professor of Radiology in the School of Medicine at The Johns Hopkins University (JHU), is a recognized world leader in the development of biomechanical parameters of hip structure derived from densitometric information. Professor Beck's HSA method and its prediction of bone strength has been subject of over 30 peer-reviewed publications.

The HSA method was used in the analysis of a number of major studies including the 3rd National Health and Nutrition Examination Survey (NHANES III) and the Eli Lilly and Company Multiple Outcomes of Raloxifene (MORE) trial.

Dr. Beck notes that while Bone Mineral Density (BMD) is recognized as a strong predictor of fracture risk in osteoporosis, structural effects on bones that are important in determining their mechanical strength cannot be easily determined from BMD alone. "Hip Structure Analysis algorithms allow us to calculate both the BMD as well as the structural geometry that underlies bone strength from DXA measurements. I believe this will result in more definitive measures of bone health."

"This agreement is another example of Hologic's commitment to provide cutting edge tools in skeletal health," commented Brad Herrington, Hologic Vice President of Skeletal Health Imaging. "HSA is the leading hip structure analysis method for DXA scans in research and pharmaceutical studies. We intend to take this tool through the FDA and other regulatory approval processes and offer it to our bone densitometer customers."

Hologic will be the exclusively licensed major bone densitometer manufacturer to incorporate HSA into its products.

HSA™ is a trademark of The Johns Hopkins University Applied Physics Laboratory.

About Hologic

Hologic Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, and mini C-arm and extremity MRI imaging for orthopedic applications. For more information visit www.hologic.com.

About The Johns Hopkins University Applied Physics Laboratory

The Applied Physics Laboratory is a not-for-profit laboratory and division of The Johns Hopkins University. APL conducts research and development primarily for national security and for non-defense projects of global significance. For information, visit www.jhuapl.edu.

Forward-Looking Disclaimer

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the anticipated performance, efficiency, cost and acceptance of HSA and Hologic's bone densitometer systems. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Hologic cannot assure that it will be able to obtain the necessary FDA approvals or clearances to integrate HSA into its bone densitometry products on a timely basis or within budget if at all, or that any such product, once developed will perform as anticipated or be successful. Without limiting the foregoing, factors that could cause actual results to materially differ include, without limitation: uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, such as the ability to obtain FDA approval or clearances to market products developed, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and reimbursement policies for the use of Hologic's products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact:

Brad Herrington
VP, Skeletal Health Imaging
Phone: 781 999 7346
bherrington@hologic.com

James Culley, PhD
Marketing Manager
Phone: 781 999 7583
jculley@hologic.com